

CORPORATE PRESENTATION

Laboratórios Basi



Agenda

01

FHC Group

Where do Basi Laboratories fit within the Group, what is the scale of the FHC Group, and what is its role in the healthcare sector?

02

Laboratórios Basi

What is our vision and mission?
What differentiates us in the market, and how are our solutions used?





01

FHC
Group



ABOUT THE GROUP

FHC GROUP

FHC Group is one of the leading business groups in Portugal's pharmaceutical sector. It is wholly privately owned by Portuguese shareholders and has a presence across five continents and throughout the entire pharmaceutical value chain, with recognised expertise in manufacturing, distribution across the outpatient and hospital markets, export and internationalisation, healthcare R&D, and information technology.

544 M€

REVENUE

24 M€

EBITDA

820

EMPLOYEES

65

COUNTRIES WITH A PRESENCE

2025 Consolidated Key Performance Indicators

FHC GROUP

Business Areas

MANUFACTURING



TECHNOLOGY CONSULTING & INNOVATION



**ZEONE
CONSULTING**

CLINICAL RESEARCH



RETAIL



LOGISTICS & DISTRIBUTION



Empifarma



SVP PHARMA

lamar

A scientist wearing a white lab coat, a blue surgical mask, and a white hairnet is working inside a biosafety cabinet. The cabinet's glass door is open, revealing several racks filled with small vials and test tubes. The scientist is holding a small vial with both hands, appearing to be transferring or examining its contents. The background is a solid blue wall.

02

Laboratórios
Basi

WHO WE ARE

Taking care worldwide

Laboratórios Basi is recognised as a leading company in its field, with a history spanning more than 50 years. Its journey has been shaped by a wealth of events, experiences and learnings, with a strong commitment to building and reinforcing a corporate identity that reflects its core values.

+50


YEARS OF
HISTORY

02

MANUFACTURING
FACILITIES

+65

COUNTRIES



ABOUT US

Mission, Vision & Values

MISSION

To develop, manufacture, commercialise and distribute medicines and therapeutic solutions globally, underpinned by European standards of excellence in quality and supported by innovative technologies, while maintaining a competitive and flexible approach.

VISION

To be the leading national pharmaceutical manufacturer and a European benchmark for Quality, Flexibility, Technological Innovation and Competitiveness.

VALUES

Trust, Ethics, Innovation, Courage & Agility.



Business Areas

- | | | |
|----|--------------------------|--|
| 01 | Pharmaceutical Portfolio | Fast-growing therapeutic solutions. More than 320 registered pharmaceutical products across 18 different therapeutic areas. |
| 02 | Quality Control | <p>An internationally recognised centre of excellence, equipped with state-of-the-art physicochemical and microbiological analytical technologies, enabling a comprehensive range of testing on raw materials, packaging materials and finished products, including the validation of analytical methods.</p> <p>The laboratory is also prequalified by the WHO for analytical testing, further strengthening its international recognition and credibility.</p> |
| 03 | Contract Manufacturing | The two manufacturing facilities enable us to offer contract manufacturing services across a broad range of pharmaceutical dosage forms, including small and large volume parenterals; gels, creams and ointments; syrups, oral solutions and suspensions; cutaneous solutions; and enemas. |
| 04 | Licensing | A broad portfolio of products with complete EU-CTD documentation packages, available for licensing to partners across five continents. We leverage our extensive technical expertise and in-depth product knowledge to deliver value to our customers. |
| 05 | R&D | Research and Development is a strategic area for the Group, with Innovation serving as a key pillar of our business. We are committed to developing innovative healthcare products and pharmaceutical dosage forms. |

Strategic Priorities

- | | | | |
|----|--|----|--|
| 01 | To become a global player in the pharmaceutical industry | 05 | Continuously invest in research, development and innovation |
| 02 | To become a leading reference in fluid therapy | 06 | Increase production capacity through technological innovation and process optimisation |
| 03 | Strengthen the recognition and visibility of the Basi brand and portfolio | 07 | Increase revenue and export capacity |
| 04 | Expand our presence in the Portuguese, Spanish, United Kingdom, French and South African markets | 08 | Strengthen environmental sustainability and resource efficiency |

OFFERING

Portfolio

MEDICINES

MEDICAL DEVICES

SUPPLEMENTS

DERMOCOSMETICS

Fast-growing therapeutic solutions

18

DIVERSE
THERAPEUTIC
AREAS


+320

REGISTERED
PHARMACEUTICAL
PRODUCTS

+65

COUNTRIES WHERE OUR
TREATMENTS ARE
AVAILABLE





PRODUCTION CAPACITY

Liquid & Semi-Solid Manufacturing

ANNUAL CAPACITY · 3 SHIFTS

SEMI-SOLID PRODUCTION LINE

31.000.000 units

Weighing Room
Semi-Solid Compounding Room
Semi-Solid Filling Room 1
Semi-Solid Filling Room 2
Semi-Solid Packaging Area

LIQUID PRODUCTION LINE

16.000.000 units

Liquid Compounding Room
Liquid Filling Room
Liquid Packaging Area
— Labelling Machine

LIQUID DROPS PRODUCTION LINE

5.000.000 units

Liquid Drops Filling Room
Liquid Drops Packaging Area
— Labelling Machine

PRODUCTION CAPACITY

Injectable Manufacturing

LARGE-VOLUME INJECTABLES

LVP

ANNUAL CAPACITY · 3SHIFTS

38.000 – 50.000.000 units

100ml

250 ml

500 ml

1000 ml

LVP PRODUCTION LINE

- Weighing Room
- Washing Room
- Compounding Room
- LVP Injection Room
- LVP Filling Room
- LVP Packaging Area

- LVP Handling System
- LVP Sterilisation Autoclave
- LVP Inspection Machine
- LVP Labelling Machine
- LVP Cartoning Machine
- LVP Palletising System

SMALL-VOLUME INJECTABLES

SVP

ANNUAL CAPACITY · 3SHIFTS

70.000 – 150.000.000 units

1 and 2 ml

5 ml


10 ml

20 ml

SVP PRODUCTION LINE

- Compounding Room
- Washing Room
- Washing Machine Room
- SVP Filling Room
- Non-Sterile Autoclave Room
- SVP Packaging Area

- SVP Inspection Machine
- SVP Labelling Machine
- SVP Blister Packaging Machine
- SVP Cartoning Machine



FACILITIES

Basi Campus

139.758,00 m²

BASI CAMPUS AREA

21.592,00 m²

IJM INDUSTRIAL AREA

7.000,00 m²


LSM INDUSTRIAL AREA

IJM *Injectables*

Production Area (4,788.86 m²) · Administrative Area · Cafeteria · Warehouses (8,822.91 m²) · Stability Storage Area (665 m²)

LSM *Liquids & Semi-Solids*

Production Area (1,439.80 m²) · Quality Control (1,693.25 m²) · PPD Department · Warehouses (3,280.00 m²)



FACILITIES

Basi Campus – Expansion

142.533,00 m²

BASI CAMPUS AREA

25.912,00 m²

IJM INDUSTRIAL AREA

8.240,00 m²


LSM INDUSTRIAL AREA

IJM *Injectables*


Production Area (4,788.86 m²) · Administrative Area · Cafeteria · Warehouses (8,822.91 m²) · Stability Storage Area (665 m²) · **LVP & SVP Expansion (4,320 m²)**

LSM *Liquids & Semi-Solids*

Production Area (1,439.80 m²) · Quality Control (1,693.25 m²) · PPD Department · Warehouses (3,280.00 m²) · **PPD Expansion (1,240 m²)**



Value-Added Products



Our R&D team is committed to optimising every aspect of our products, enhancing the value of both our portfolio and those of our partners.

1 Free from Colourants and Preservatives

Reducing exposure to unnecessary excipients

2 Stopper Cap

Reducing waste and enhancing perceived quality

3 Oral Syringe

Improving treatment adherence and ease of administration

4 Sugar Free

Suitable for people with diabetes

5 Child-Resistant Cap

Enhancing product safety

6 Improved Impurity Profile

Optimised formulation to extend product shelf life

7 Improved Taste

Improved organoleptic properties to enhance treatment adherence

INNOVATION

Value-Added Products

Functional

- High-strength, 360° hanging device
- Fully collapsible transparent bottle
- Two-way volume scale on the bottle
- Large headspace for additive incorporation
- 2 independent injection ports

Eco-Friendly Manufacturing


- Reduced energy consumption (-13%)
- Lighter packaging (-30% plastic)
- 1% plastic waste

Innovative

The technical advantages of the packaging are made possible by a state-of-the-art Industry 4.0 manufacturing facility

basiflex

- 1 360° Hanging Device
- 2 Transparent, Collapsible Bottle
- 3 Large Headspace volume
- 4 2 Independent Injection Ports




Active Markets

65

Countries


Basi Portfolio



40

Countries

Licensing Agreements





Thank you